Search results
Found 371 matches for
Neutralising mAbs, a form of anti-viral medicine, are being explored as an attractive option to treat symptoms of COVID-19 and in some cases prevent infection. But what are the pros and cons of this type of treatment and what should regulators consider before granting approval?
Karene Argoud
Kennedy Research Scientists
Karene Argoud - Single-Cell and Spatial Genomics Operations Technician
Hanna Boddy
Kennedy Professional Services
Hanna Boddy - Executive Assistant to the Director of the Kennedy Institute
Veronika Pfannenstil
Kennedy Research Scientists
Veronika Pfannenstil - Postdoctoral Research Assistant
Tarrion Baird
Kennedy Research Scientists
Tarrion Baird - Postdoctoral Research Associate in Computational Biology
Gemma Laws
Kennedy Research Scientists
Gemma Laws - Postdoctoral Researcher in Intestinal Immune Responses
Chik On Choy
Kennedy Research Scientists
BSc, MSc, MBA, MPhil (Cantab) Chik On Choy - OCMS Project Manager
Shengpan Zhang
Kennedy Research Scientists
Shengpan Zhang - EvolveImmune Postdoctoral Research Assistant
Tonia Vincent
Education and Training Kennedy Principal Investigators
FRCP, PhD Tonia Vincent - Professor of Musculoskeletal Biology & Honorary rheumatologist
Mark Coles
Education and Training Graduate studies Kennedy Principal Investigators
PhD, FRSB Mark Coles - Professor of Immunology
Kim Midwood
Education and Training Graduate studies Kennedy Principal Investigators
BSc (Hons), PhD Kim Midwood - Professor of Matrix Biology